Investigating the Efficacy of Probiotics in Enhancing Gastrointestinal and Immunological Health
A Study on the Role of Ligilactobacillus Salivarius LS97 in Modulating Gut Microbiota and Immune System Function
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Fei Xu
- Phone Number: 86 13671979116
- Email: xu.fei@haut.edu.cn
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 210095
- Xu fei
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing to undergo 3 follow-up visits during the intervention period
- Be willing to provide blood, urine and stool samples 2 times during the intervention period
- Good eyesight, can read and write, can wear glasses
- Have good hearing and be able to hear and understand all instructions during the intervention
Exclusion Criteria:
- Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)
- Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor prolonged coma - not including general anaesthesia)
- Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia psychosis, bipolar disorder
- Take medication for depression or low mood
- Internal organ failure (heart, liver or kidney failure, etc.)
- Have received radiation or chemotherapy in the past
- have undergone a general anesthesia procedure/procedure within the past three years, or plan to undergo a general anesthesia procedure/procedure within the next 3 months during this trial period
- Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo group
Every day to give 3 g maltodextrin intervention for 8 weeks.
|
The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
|
|
Active Comparator: Probiotic group
Intervention with Ligilactobacillus salivarius LS97 (30 billion CFU/day, 3g) was administered daily for 8 weeks.
|
The trial period of this study lasts for 2 months (8 weeks), during which each participant will have 3 visits (at month 0, month 1, and month 2).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the composition of fecal microbiota before and after intervention.
Time Frame: Week 0 and Week 8
|
Analyzed by 16S rRNA sequencing.
|
Week 0 and Week 8
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- WK20250307
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.